Pfizer, Zhejiang to establish new JV for generic medicines
As per the agreement, the JV will be named as Hisun Pfizer Pharmaceutical. Under the contract, Hisun will own 51% and Pfizer will own 49%, and the aggregate
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The BARDA contract includes pre-clinical efficacy and toxicology studies; clinical studies; manufacturing activities; and associated regulatory activities of TP-434. The contract includes a 12-month base period with committed